Evidence map›Paper›PMID 32086779›Full record

ArticleTranslational stroke research2020

Modeling Mixed Vascular and Alzheimer's Dementia Using Focal Subcortical Ischemic Stroke in Human ApoE4-TR:5XFAD Transgenic Mice.

Eric Y Hayden, Julia M Huang, Malena Charreton, Stefanie M Nunez, Jennifer N Putman, Bruce Teter, Jason T Lee, Andrew Welch, Sally Frautschy, Gregory Cole and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational stroke research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. A review of animal models of vascular dementia.Molecular biology reports · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Eric Y HaydenDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, 635 Charles E. Young Dr. South, Neuroscience Research Building, Rm 415, Los Angeles, CA, 90095, USA.
Julia M HuangDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, 635 Charles E. Young Dr. South, Neuroscience Research Building, Rm 415, Los Angeles, CA, 90095, USA.
Malena CharretonDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, 635 Charles E. Young Dr. South, Neuroscience Research Building, Rm 415, Los Angeles, CA, 90095, USA.
Stefanie M NunezDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, 635 Charles E. Young Dr. South, Neuroscience Research Building, Rm 415, Los Angeles, CA, 90095, USA.
Jennifer N PutmanDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, 635 Charles E. Young Dr. South, Neuroscience Research Building, Rm 415, Los Angeles, CA, 90095, USA.
Bruce TeterDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, 635 Charles E. Young Dr. South, Neuroscience Research Building, Rm 415, Los Angeles, CA, 90095, USA.
Jason T LeeCrump Institute for Molecular Imaging, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Andrew WelchThe Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
Sally FrautschyDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, 635 Charles E. Young Dr. South, Neuroscience Research Building, Rm 415, Los Angeles, CA, 90095, USA.
Gregory ColeDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, 635 Charles E. Young Dr. South, Neuroscience Research Building, Rm 415, Los Angeles, CA, 90095, USA.
Edmond TengDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, 635 Charles E. Young Dr. South, Neuroscience Research Building, Rm 415, Los Angeles, CA, 90095, USA.
Jason D HinmanDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, 635 Charles E. Young Dr. South, Neuroscience Research Building, Rm 415, Los Angeles, CA, 90095, USA. jhinman@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-0872-5044
University of California, Los Angeles · USUniversity of Aberdeen · GB

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Molecular Mechanisms of Axonal Degeneration After White Matter StrokeK08NS083740 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HINMAN, JASON D · 2013 to 2017
$831k
Neuroinflammation and Neurodegeneration in a Transgenic Alzheimer Rat with Vascular DiseaseI01BX003485 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI FRAUTSCHY, SALLY ANN · 2017 to 2022
–
American Heart Association (US) Undergraduate Student ResearchBLRD VA I01 BX003485Clinical and Translational Science Institute University of California Los Angeles UL1TR000124NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NINDS NIH HHS K08 NS083740NINDS NIH HHS NS083740
6 · The paper itself

Abstract

Subcortical white matter ischemic lesions are increasingly recognized to have pathologic overlap in individuals with Alzheimer's disease (AD). The interaction of white matter ischemic lesions with amyloid pathology seen in AD is poorly characterized. We designed a novel mouse model of subcortical white matter ischemic stroke and AD that can inform our understanding of the cellular and molecular mechanisms of mixed vascular and AD dementia. Subcortical white matter ischemic stroke underlying forelimb motor cortex was induced by local stereotactic injection of an irreversible eNOS inhibitor. Subcortical white matter ischemic stroke or sham procedures were performed on human ApoE4-targeted-replacement (TR):5XFAD mice at 8 weeks of age. Behavioral tests were done at 7, 10, 15, and 20 weeks. A subset of animals underwent

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsApolipoprotein E4BrainBrain IschemiaDisease Models, AnimalHumansIschemic StrokeMice, TransgenicAmyloid beta-PeptidesApolipoprotein E4Alzheimer’s diseaseAmyloidLacunar strokeModelingWhite matter disease

Identifiers

PMID32086779
PMCPMC10075511
OpenAlexW3007064884

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.